Related Experiment Video
Updated: Jun 1, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
HIV and HAART-Associated Dyslipidemia
Eoin R Feeney1, Patrick W G Mallon
1HIV Molecular Research Group, School of Medicine and Medical Science, University College Dublin, Dublin, Ireland.
Highly active antiretroviral therapy (HAART) improves HIV survival but can cause dyslipidemia, increasing cardiovascular disease risk. This review covers HIV and ART-associated dyslipidemia, its causes, and management strategies.
Area of Science:
- Infectious Diseases
- Cardiology
- Pharmacology
Background:
- Highly active antiretroviral therapy (HAART) has significantly improved life expectancy for individuals with human immunodeficiency virus type 1 (HIV).
- Despite HAART's success, HIV-infected patients face increased morbidity and mortality from non-AIDS conditions, notably premature cardiovascular disease, liver, and renal failure.
- Dyslipidemia is a primary driver of elevated cardiovascular disease risk in HIV-infected patients, linked to aging, long-term HIV infection, and antiretroviral therapy (ART).
Purpose of the Study:
- To review the clinical presentation of dyslipidemia associated with HIV infection and ART.
- To elucidate the pathophysiology of HIV and ART-associated dyslipidemia, including links to specific antiretroviral medications.
- To propose evidence-based screening and management strategies for dyslipidemia in the context of HIV and ART.
Main Methods:
- This is a review article synthesizing current knowledge on HIV and ART-associated dyslipidemia.
- Literature search and analysis focusing on clinical presentation, pathophysiology, and treatment of dyslipidemia in HIV-infected patients.
- Examination of associations between specific antiretroviral drugs and dyslipidemia development.
Main Results:
- Dyslipidemia is a prevalent complication in HIV-infected individuals undergoing ART.
- Specific antiretroviral medications are associated with different patterns and severity of dyslipidemia.
- The pathophysiology involves complex interactions between HIV, ART, and host factors contributing to premature cardiovascular disease.
Conclusions:
- HIV and ART-associated dyslipidemia is a significant clinical challenge requiring vigilant monitoring.
- Understanding the specific drug-associated risks is crucial for personalized treatment and prevention strategies.
- Effective screening and management protocols are essential to mitigate cardiovascular risk in this growing patient population.
Related Concept Videos
Retrovirus Life Cycles
Sexually Transmitted Infections
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Inhibitors of Virion Maturation and Assembly
